Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Description

This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with

Conditions

Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with

Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Condition
Primary Sclerosing Cholangitis
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Mayo Clinic in Arizona, Scottsdale, Arizona, United States, 85259

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults aged 18-75 irrespective of gender who have undergone LT for PSC or PSC-related liver malignancy between 1 year and 7 years (inclusive) prior to study enrollment
  • * Absence of rPSC at time of study enrollment
  • * At least one of the following additional features that increase risk of rPSC
  • * LT performed for cholangiocarcinoma
  • * Concurrent inflammatory bowel disease
  • * Any episode of cytomegalovirus viremia in the post-transplant period before study enrollment
  • * Any episode of acute cellular rejection in the post-transplant period before the study enrollment
  • * If target enrollment of 40 patients is not achieved during the first 6 months of study, we will remove f(iii) inclusion criteria to expand enrollment to any patient meeting the other inclusion/exclusion criteria.
  • * Due to lab requirements, we will only enrol patients who are within a 3 hour driving distance of Mayo Clinic Arizona and/or are willing to travel to Mayo Clinic Arizona at 4 month intervals during the study at own cost.
  • * Presence of ischemic cholangiopathy which can mimic rPSC
  • * LT performed for primary biliary cholangitis or autoimmune hepatitis, or PSC with overlapping primary biliary cholangitis or autoimmune hepatitis, which may recur after LT and confound assessment of cholestasis
  • * Unaddressed post-LT hepatic artery compromise (e.g thrombosis, stenosis) which can mimic rPSC
  • * History of total colectomy for curative treatment of ulcerative colitis which reduces risk of rPSC
  • * Baseline GFR \<30 ml/min which precludes administration of fenofibrate
  • * Previously known intolerance or allergy to fenofibrate
  • * Other clinically significant comorbid condition, including inability to provide consent and psychiatric conditions, which in the opinion of the study team, may interfere with patient treatment, safety, assessment, or compliance with the treatment
  • * Female participants that are pregnant or planning to become pregnant

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Channa Jayasekera, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2028-07-01